Primary cutaneous, epidermotropic mycosis fungoides-like presentation: critical appraisal and description of two novel cases, broadening the spectrum of ALK+ T-cell lymphoma.
ALK
CD30
Epidermotropic
Mycosis fungoides
Primary cutaneous lymphoma
Target therapy
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
23 May 2024
23 May 2024
Historique:
received:
16
03
2024
accepted:
19
05
2024
revised:
18
04
2024
medline:
23
5
2024
pubmed:
23
5
2024
entrez:
23
5
2024
Statut:
aheadofprint
Résumé
Leading from a two-case series, including two patients receiving a diagnosis of epidermotropic T-cell lymphoma, featuring a mycosis fungoides (MF)-like clinical pattern and ALK expression and molecular alteration, we performed a critical appraisal of ALK+ primary cutaneous T-cell lymphomas (pcTCL). Considering our patients and the literature, 32 cases were retrieved, 7 of which featured an MF-like clinical picture over a 4-to-20-year period. MF-like cases show distinctive histology, comprising a predominantly epidermotropic infiltration of small-to-large, atypical-to-pleomorphic, with few anaplastic cells, negligible-to-intense CD30-expression, and a CD4+/cytotoxic granule+ phenotype. These features should prompt a search for ALK expression captured by the ALK D5F3 clone. Bona fide ALK+ pcTCL is very rare, and existent data suggest the presence of a broader pattern of disease, including instances mimicking MF and/or primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma. The major challenges in dealing with this subset include prodromal phases, misinterpreted as inflammatory dermatosis or parapsoriasis/early phase MF both clinically and histologically, while recognition of its ALK-driven biology is hampered both by the unusual clinic-pathologic pattern of the disease, which stands apart from the classical (i.e., nodal) picture of ALK+ anaplastic large cell lymphoma and by the low sensitivity of ALK1 clone. Data on its optimal management are far from being conclusive: An MF-like approach is currently chosen, but depending on CD30 and, most notably, ALK expression, a targeted therapy could be envisaged in advanced stages, as clinical response to ALK inhibition was documented in one patient.
Identifiants
pubmed: 38780617
doi: 10.1007/s00428-024-03832-6
pii: 10.1007/s00428-024-03832-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Torres-Cabala CA (2020) Diagnosis of T-cell lymphoid proliferations of the skin: putting all the pieces together. Mod Pathol Off J U S Can Acad Pathol Inc 33(Suppl 1):83–95. https://doi.org/10.1038/s41379-019-0397-3
doi: 10.1038/s41379-019-0397-3
Goodlad JR, Cerroni L, Swerdlow SH (2023) Recent advances in cutaneous lymphoma-implications for current and future classifications. Virchows Arch Int J Pathol 482(1):281–298. https://doi.org/10.1007/s00428-022-03421-5
doi: 10.1007/s00428-022-03421-5
Scarisbrick JJ, Quaglino P, Prince HM et al (2019) The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol 181(2):350–357. https://doi.org/10.1111/bjd.17258
doi: 10.1111/bjd.17258
pubmed: 30267549
Van Arnam JS, Lim MS, Elenitoba-Johnson KSJ (2018) Novel insights into the pathogenesis of T-cell lymphomas. Blood 131(21):2320–2330. https://doi.org/10.1182/blood-2017-11-764357
doi: 10.1182/blood-2017-11-764357
pubmed: 29666117
Langerak AW, Groenen PJTA, Brüggemann M et al (2012) EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia 26(10):2159–2171. https://doi.org/10.1038/leu.2012.246
doi: 10.1038/leu.2012.246
pubmed: 22918122
pmcid: 3469789
Abdulla FR, Sarpa H, Cassarino D (2013) The expression of ALK in mycosis fungoides, stage IA. J Cutan Pathol 40(3):348–350. https://doi.org/10.1111/cup.12055
doi: 10.1111/cup.12055
pubmed: 23205942
Quintanilla-Martinez L, Jansen PM, Kinney MC, Swerdlow SH, Willemze R (2013) Non-mycosis fungoides cutaneous T-cell lymphomas: report of the 2011 Society for Hematopathology/European Association for Haematopathology workshop. Am J Clin Pathol 139(4):491–514. https://doi.org/10.1309/AJCP83AOQTMLOJTM
doi: 10.1309/AJCP83AOQTMLOJTM
pubmed: 23525618
Wehkamp U, Oschlies I, Nagel I et al (2015) ALK-positive primary cutaneous T-cell-lymphoma (CTCL) with unusual clinical presentation and aggressive course. J Cutan Pathol 42(11):870–877. https://doi.org/10.1111/cup.12547
doi: 10.1111/cup.12547
pubmed: 26053561
Barbé J, Escobar G, Marzouki-Zerouali A, Lardenois E, Schmutz JL, Bursztejn AC (2021) Disseminated indolent ALK-positive primary cutaneous anaplastic large cell lymphoma (C-ALCL) lasting for 10 years. Int J Dermatol 60(4):e146–e147. https://doi.org/10.1111/ijd.15324
doi: 10.1111/ijd.15324
pubmed: 33249555
Su LD, Schnitzer B, Ross CW et al (1997) The t(2;5)-;associated p80 NPM/ALK fusion protein in nodal and cutaneous CD30+ lymphoproliferative disorders. J Cutan Pathol 24(10):597–603. https://doi.org/10.1111/j.1600-0560.1997.tb01090.x
doi: 10.1111/j.1600-0560.1997.tb01090.x
pubmed: 9449486
Hosoi M, Ichikawa M, Imai Y, Kurokawa M (2010) A case of anaplastic large cell lymphoma, ALK positive, primary presented in the skin and relapsed with systemic involvement and leukocytosis after years of follow-up period. Int J Hematol 92(4):667–668. https://doi.org/10.1007/s12185-010-0708-4
doi: 10.1007/s12185-010-0708-4
pubmed: 20976631
Campo E, Chott A, Kinney MC et al (2006) Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece. Histopathology 48(5):481–504. https://doi.org/10.1111/j.1365-2559.2006.02369.x
doi: 10.1111/j.1365-2559.2006.02369.x
pubmed: 16623775
pmcid: 1448691
Chao-Lo MPG, King-Ismael D, Lopez RA (2008) Primary cutaneous CD30+ anaplastic large cell lymphoma: report of a rare case. J Dermatol Case Rep 2(3):31–34. https://doi.org/10.3315/jdcr.2008.1013
doi: 10.3315/jdcr.2008.1013
pubmed: 21886709
pmcid: 3157779
Kadin ME, Pinkus JL, Pinkus GS et al (2008) Primary cutaneous ALCL with phosphorylated/activated cytoplasmic ALK and novel phenotype: EMA/MUC1+, cutaneous lymphocyte antigen negative. Am J Surg Pathol 32(9):1421–1426. https://doi.org/10.1097/PAS.0b013e3181648d6d
doi: 10.1097/PAS.0b013e3181648d6d
pubmed: 18670345
Chan DV, Summers P, Tuttle M et al (2011) Anaplastic lymphoma kinase expression in a recurrent primary cutaneous anaplastic large cell lymphoma with eventual systemic involvement. J Am Acad Dermatol 65(3):671–673. https://doi.org/10.1016/j.jaad.2010.06.016
doi: 10.1016/j.jaad.2010.06.016
pubmed: 21839333
pmcid: 3156415
Kumaran MS, Jithendriya M, Nagaraj P, Tirumalae R, Jayaseelan E (2012) Anaplastic lymphoma kinase-positive primary cutaneous anaplastic large cell lymphoma--is it a new variant? Indian J Dermatol Venereol Leprol 78(3):354–357. https://doi.org/10.4103/0378-6323.95454
doi: 10.4103/0378-6323.95454
pubmed: 22565437
Oschlies I, Lisfeld J, Lamant L et al (2013) ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study. Haematologica 98(1):50–56. https://doi.org/10.3324/haematol.2012.065664
doi: 10.3324/haematol.2012.065664
pubmed: 22773605
pmcid: 3533659
Xue D, Li X, Ren Y, Liu Q, Yen Y, Xue L (2015) Primary cutaneous anaplastic large cell lymphoma with positive ALK expression and a rapidly progressive cutaneous Nodule. Int J Surg Pathol 23(4):333–335. https://doi.org/10.1177/1066896915568993
doi: 10.1177/1066896915568993
pubmed: 25633507
Pulitzer M, Ogunrinade O, Lin O, Steinherz P (2015) ALK-positive (2p23 rearranged) anaplastic large cell lymphoma with localization to the skin in a pediatric patient. J Cutan Pathol 42(3):182–187. https://doi.org/10.1111/cup.12446
doi: 10.1111/cup.12446
pubmed: 25404214
pmcid: 5108361
Fauconneau A, Pham-Ledard A, Cappellen D et al (2015) Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases. Br J Dermatol 172(6):1547–1554. https://doi.org/10.1111/bjd.13690
doi: 10.1111/bjd.13690
pubmed: 25645336
Chen H, Xiong JS, Sheng N et al (2017) Primary Cutaneous Sarcomatoid Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma With Linear Distributional Lesions. Am J Dermatopathol 39(11):863–866. https://doi.org/10.1097/DAD.0000000000000925
doi: 10.1097/DAD.0000000000000925
pubmed: 29053547
Tokuyama M, Kurashige Y, Ota T et al (2017) Pediatric case of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma forming a solitary skin tumor on the forearm. J Dermatol 44(4):465–467. https://doi.org/10.1111/1346-8138.13688
doi: 10.1111/1346-8138.13688
pubmed: 27864829
Melchers RC, Willemze R, van de Loo M et al (2020) Clinical, histologic, and molecular characteristics of anaplastic lymphoma kinase-positive primary cutaneous anaplastic large cell lymphoma. Am J Surg Pathol 44(6):776–781. https://doi.org/10.1097/PAS.0000000000001449
doi: 10.1097/PAS.0000000000001449
pubmed: 32412717
Taheri D, Zahavi DJ, Del Carmen RM et al (2016) For staining of ALK protein, the novel D5F3 antibody demonstrates superior overall performance in terms of intensity and extent of staining in comparison to the currently used ALK1 antibody. Virchows Arch Int J Pathol 469(3):345–350. https://doi.org/10.1007/s00428-016-1969-y
doi: 10.1007/s00428-016-1969-y
Moayed-Alaei L, Vargas AC, Adybeik D, Maclean F, Moir D (2022) Analyzing the morphological spectrum of epithelioid fibrous histiocytoma and the immunohistochemical performance of the ALK D5F3 and ALK1 clones. Hum Pathol 120:46–56. https://doi.org/10.1016/j.humpath.2021.12.004
doi: 10.1016/j.humpath.2021.12.004
pubmed: 34929229
Bironzo P, Melocchi L, Monica V et al (2022) Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study. Pathologica 114(4):278–287. https://doi.org/10.32074/1591-951X-756
doi: 10.32074/1591-951X-756
pubmed: 36083243
pmcid: 9624140
Martin D, Smith SC, Chesney A, Jackson-Cook C, Pillappa R (2022) Too sensitive or just right? Am J Clin Pathol 158(2):283–290. https://doi.org/10.1093/ajcp/aqac043
doi: 10.1093/ajcp/aqac043
pubmed: 35482487
Noguchi K, Ikawa Y, Takenaka M et al (2022) Characterisation of two tumour cell populations in the small cell variant of anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Br J Haematol 196(1):241–243. https://doi.org/10.1111/bjh.17776
doi: 10.1111/bjh.17776
pubmed: 34420216
Shustov A, Soma L (2019) Anaplastic large cell lymphoma: contemporary concepts and optimal management. Cancer Treat Res 176:127–144. https://doi.org/10.1007/978-3-319-99716-2_6
doi: 10.1007/978-3-319-99716-2_6
pubmed: 30596216
Brugières L, Cozic N, Houot R et al (2023) Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial. Eur J Cancer Oxf Engl 1990 191:112984. https://doi.org/10.1016/j.ejca.2023.112984
doi: 10.1016/j.ejca.2023.112984